These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 37882941)

  • 21. Gastrointestinal Safety of Direct Oral Anticoagulants: A Large Population-Based Study.
    Abraham NS; Noseworthy PA; Yao X; Sangaralingham LR; Shah ND
    Gastroenterology; 2017 Apr; 152(5):1014-1022.e1. PubMed ID: 28043907
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Four-factor Prothrombin Complex Concentrate for Reversal of Factor Xa Inhibitors versus Warfarin in Life-threatening Bleeding.
    Rech MA; Masic D; Hammond DA
    West J Emerg Med; 2021 Feb; 22(2):163-169. PubMed ID: 33856296
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of 4-factor PCC reversal of apixaban and rivaroxaban versus warfarin for intracranial hemorrhage.
    Pasciolla S; Wojcik K; Kavi T; Green D; Shaikh H; Jankowitz B; Igneri LA
    J Thromb Thrombolysis; 2022 Jul; 54(1):74-81. PubMed ID: 34837144
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Apixaban and rivaroxaban anti-Xa level utilization and associated bleeding events within an academic health system.
    Jakowenko N; Nguyen S; Ruegger M; Dinh A; Salazar E; Donahue KR
    Thromb Res; 2020 Dec; 196():276-282. PubMed ID: 32947066
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation and Previous Stroke or Transient Ischemic Attack.
    Coleman CI; Peacock WF; Bunz TJ; Alberts MJ
    Stroke; 2017 Aug; 48(8):2142-2149. PubMed ID: 28655814
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association of Rivaroxaban vs Apixaban With Major Ischemic or Hemorrhagic Events in Patients With Atrial Fibrillation.
    Ray WA; Chung CP; Stein CM; Smalley W; Zimmerman E; Dupont WD; Hung AM; Daugherty JR; Dickson A; Murray KT
    JAMA; 2021 Dec; 326(23):2395-2404. PubMed ID: 34932078
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Major Bleeding Risk During Anticoagulation with Warfarin, Dabigatran, Apixaban, or Rivaroxaban in Patients with Nonvalvular Atrial Fibrillation.
    Adeboyeje G; Sylwestrzak G; Barron JJ; White J; Rosenberg A; Abarca J; Crawford G; Redberg R
    J Manag Care Spec Pharm; 2017 Sep; 23(9):968-978. PubMed ID: 28854073
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Factor VIII Inhibitor Bypassing Activity (FEIBA) Reversal for Apixaban and Rivaroxaban in Patients With Acute Intracranial and Nonintracranial Hemorrhage.
    Hunt AR; Coffeen SN; Shiltz DL; Ice C; Parker J
    Ann Pharmacother; 2021 Dec; 55(12):1455-1466. PubMed ID: 33843267
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy of prothrombin complex concentrate in the management of oral factor Xa inhibitors associated major bleed assessed by ISTH and ANNEXA-4 criteria.
    Dev P; Abousaab C; Zhou C; Sarode R
    J Thromb Thrombolysis; 2022 Feb; 53(2):249-256. PubMed ID: 34373984
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Risks of post-colonoscopic polypectomy bleeding and thromboembolism with warfarin and direct oral anticoagulants: a population-based analysis.
    Lau LH; Guo CL; Yip TC; Mak JW; Wong SH; Lam KL; Wong GL; Ng SC; Chan FK
    Gut; 2022 Jan; 71(1):100-110. PubMed ID: 33619167
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prothrombin complex concentrate for direct factor Xa inhibitor-associated bleeding or before urgent surgery.
    Shaw JR; Almujalli AA; Xu Y; Levy JH; Schulman S; Siegal D; Dowlatshahi D; Tokessy M; Buyukdere H; Carrier M; Castellucci LA
    Thromb Res; 2024 Nov; 243():109172. PubMed ID: 39362177
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Final Study Report of Andexanet Alfa for Major Bleeding With Factor Xa Inhibitors.
    Milling TJ; Middeldorp S; Xu L; Koch B; Demchuk A; Eikelboom JW; Verhamme P; Cohen AT; Beyer-Westendorf J; Gibson CM; Lopez-Sendon J; Crowther M; Shoamanesh A; Coppens M; Schmidt J; Albaladejo P; Connolly SJ;
    Circulation; 2023 Mar; 147(13):1026-1038. PubMed ID: 36802876
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prothrombin Complex Concentrate before Urgent Surgery in Patients Treated with Rivaroxaban and Apixaban.
    Barzilai M; Kirgner I; Steimatzky A; Salzer Gotler D; Belnick Y; Shacham-Abulafia A; Avivi I; Raanani P; Yahalom V; Nakav S; Varon D; Yussim E; Bachar GN; Spectre G
    Acta Haematol; 2020; 143(3):266-271. PubMed ID: 31610537
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of prothrombin complex concentrate in patients treated with rivaroxaban or apixaban compared to warfarin presenting with major bleeding.
    Arachchillage DRJ; Alavian S; Griffin J; Gurung K; Szydlo R; Karawitage N; Laffan M
    Br J Haematol; 2019 Mar; 184(5):808-816. PubMed ID: 30515764
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Administration of 4-Factor Prothrombin Complex Concentrate as an Antidote for Intracranial Bleeding in Patients Taking Direct Factor Xa Inhibitors.
    Grandhi R; Newman WC; Zhang X; Harrison G; Moran C; Okonkwo DO; Ducruet AF
    World Neurosurg; 2015 Dec; 84(6):1956-61. PubMed ID: 26341438
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of 4-factor prothrombin complex concentrate and andexanet alfa for reversal of apixaban and rivaroxaban in the setting of intracranial hemorrhage.
    Lipski M; Pasciolla S; Wojcik K; Jankowitz B; Igneri LA
    J Thromb Thrombolysis; 2023 Apr; 55(3):519-526. PubMed ID: 36566473
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation.
    Yao X; Abraham NS; Sangaralingham LR; Bellolio MF; McBane RD; Shah ND; Noseworthy PA
    J Am Heart Assoc; 2016 Jun; 5(6):. PubMed ID: 27412905
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Use of apixaban and rivaroxaban in young adults with acute venous thromboembolism: a multi-center retrospective case series.
    DeCamillo D; Ellsworth S; Kaatz S; Barnes GD
    J Thromb Thrombolysis; 2020 Nov; 50(4):844-848. PubMed ID: 32219722
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Managing target-specific oral anticoagulant associated bleeding including an update on pharmacological reversal agents.
    Siegal DM
    J Thromb Thrombolysis; 2015 Apr; 39(3):395-402. PubMed ID: 25586208
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Oral direct factor Xa inhibitor versus enoxaparin for thromboprophylaxis after hip or knee arthroplasty: Systemic review, traditional meta-analysis, dose-response meta-analysis and network meta-analysis.
    Feng W; Wu K; Liu Z; Kong G; Deng Z; Chen S; Wu Y; Chen M; Liu S; Wang H
    Thromb Res; 2015 Dec; 136(6):1133-44. PubMed ID: 26498222
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.